↓ Skip to main content

Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management

Overview of attention for article published in Frontiers in immunology, March 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
143 Dimensions

Readers on

mendeley
138 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management
Published in
Frontiers in immunology, March 2017
DOI 10.3389/fimmu.2017.00253
Pubmed ID
Authors

Seza Özen, Ezgi Deniz Batu, Selcan Demir

Abstract

Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease (AID) affecting mainly the ethnic groups originating from Mediterranean basin. The disease is characterized by self-limited inflammatory attacks of fever and polyserositis along with elevated acute phase reactants. FMF is inherited autosomal recessively; however, a significant proportion of heterozygotes also express the phenotype. FMF is caused by mutations in the MEFV gene coding for pyrin, which is a component of inflammasome functioning in inflammatory response and production of interleukin-1β (IL-1β). Recent studies have shown that pyrin recognizes bacterial modifications in Rho GTPases, which results in inflammasome activation and increase in IL-1β. Pyrin does not directly recognize Rho modification but probably affected by Rho effector kinase, which is a downstream event in the actin cytoskeleton pathway. Recently, an international group of experts has published the recommendations for the management of FMF. Colchicine is the mainstay of FMF treatment, and its regular use prevents attacks and controls subclinical inflammation in the majority of patients. Furthermore, it decreases the long-term risk of amyloidosis. However, a minority of FMF patients fail to response or tolerate colchicine treatment. Anti-interleukin-1 drugs could be considered in these patients. One should keep in mind the possibility of non-compliance in colchicine-non-responders. Although FMF is a relatively well-described AID and almost 20 years has passed since the discovery of the MEFV gene, there are still a number of unsolved problems about it such as the exact mechanism of the disease, symptomatic heterozygotes and their treatment, and the optimal management of colchicine resistance.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Turkey 1 <1%
Unknown 137 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 14%
Researcher 18 13%
Other 16 12%
Student > Bachelor 15 11%
Student > Ph. D. Student 12 9%
Other 23 17%
Unknown 34 25%
Readers by discipline Count As %
Medicine and Dentistry 47 34%
Biochemistry, Genetics and Molecular Biology 21 15%
Immunology and Microbiology 8 6%
Agricultural and Biological Sciences 6 4%
Nursing and Health Professions 3 2%
Other 9 7%
Unknown 44 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2017.
All research outputs
#22,945,287
of 25,584,565 outputs
Outputs from Frontiers in immunology
#27,826
of 32,016 outputs
Outputs of similar age
#283,773
of 323,166 outputs
Outputs of similar age from Frontiers in immunology
#407
of 441 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 32,016 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,166 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 441 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.